(Q37924816)

25 August 2017

1 reference

title

Metabolic alterations and chronic hepatitis C: treatment strategies (English)

1 reference

25 August 2017

1 reference

1 reference

1 reference

Rosa Zampino

3

0 references

Amedeo Lonardo

object named as

Amedeo Lonardo

4

0 references

author name string

Luigi E Adinolfi

1

1 reference

25 August 2017

Luciano Restivo

2

1 reference

25 August 2017

Paola Loria

5

1 reference

25 August 2017

language of work or name

English

0 references

publication date

2 September 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

14

1 reference

25 August 2017

2215-2234

1 reference

25 August 2017

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C and steatosis: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Impact of obesity on treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The global burden of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus infection: molecular pathways to metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C: a metabolic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Concluding remarks: metabolic syndrome, liver and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Dysmetabolic changes associated with HCV: a distinct syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The hepatitis C virus-associated dysmetabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance and steatosis in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C and diabetes: the inevitable coincidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance and sustained virological response in hepatitis C: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatic steatosis and insulin resistance: does etiology make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Liver disease in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Associations between serum lipids and hepatitis C antiviral treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Unscrambling hepatitis C virus-host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Fluvastatin inhibits hepatitis C replication in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hepatitis C virus infection and the risk of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.597742

10.1517/14656566.2011.597742

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference